IL-12 p80-dependent macrophage recruitment primes the host for increased survival following a lethal respiratory viral infection.
A protective immune response to a respiratory viral infection requires a series of coordinated cellular and molecular responses. We have previously demonstrated that increased expression of airway epithelial cell interleukin (IL)-12 p80, a macrophage chemoattractant, is associated with human respiratory viral infection and mediates post-viral mortality in the mouse. To better understand the role of IL-12 p80-dependent macrophage chemotaxis in mediating viral immunity, we generated a transgenic mouse strain utilizing a promoter to drive IL-12 p40 gene expression in the airway epithelium. This transgenic strain secreted biologically active IL-12 p80 in a lung-specific manner, and demonstrated a selective increase in the number of resident, unactivated airway macrophages at baseline. Following infection with a sublethal dose of mouse parainfluenza virus type 1 (Sendai virus), the transgenic mice demonstrated an earlier peak and decline in the number of airway inflammatory cells. The transgenic mice were resistant to a lethal dose of virus and this viral resistance was dependent on the increased number of airway macrophages at baseline as partial depletion prior to infection abrogated this phenotype. The survival advantage in the transgenic mice was independent of viral load but was associated with a more rapid decline in the number of airway inflammatory cells and concentrations of multiple chemokines including the CC chemokine ligand 2 (CCL2)/JE, CCL3/macrophage inflammatory protein (MIP)-1alpha, CCL4/MIP-1beta, and CCL5/RANTES. Collectively, these results suggest that IL-12 p80-driven increases in the number of resident airway macrophages prime the host for a protective immune response that can confer increased survival following a lethal respiratory viral infection.
Gunsten
Sean
S
Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St Louis, MO 63110, USA.
Mikols
Cassandra L
CL
Grayson
Mitchell H
MH
Schwendener
Reto A
RA
Agapov
Eugene
E
Tidwell
Rose M
RM
Cannon
Carolyn L
CL
Brody
Steven L
SL
Walter
Michael J
MJ
D000818:Animals; D001992:Bronchoalveolar Lavage Fluid / Q000276:immunology; D018925:Chemokines / Q000378:metabolism; D002633:Chemotaxis / Q000276:immunology; D005260:Female; D018664:Interleukin-12 / Q000276:immunology*; D008168:Lung / Q000473:pathology; D008262:Macrophage Activation / Q000276:immunology; D016676:Macrophages, Alveolar / Q000276:immunology*; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D012141:Respiratory Tract Infections / Q000276:immunology* / Q000473:pathology / Q000821:virology; D010253:Respirovirus Infections / Q000276:immunology* / Q000473:pathology / Q000821:virology; D029082:Sendai virus / Q000302:isolation & purification; D019562:Viral Load
D018925:Chemokines; C513581:IL-12 p80, mouse; D018664:Interleukin-12
J Biol Chem. 1981 Apr 25;256(8):3833-9
7217058
J Immunol. 2007 Jun 1;178(11):7251-8
17513774
J Immunol. 1998 Jan 15;160(2):588-94
9551892
Immunology. 2006 Mar;117(3):409-18
16476061
J Immunol. 1995 Jan 1;154(1):116-27
7527811
Infect Immun. 1999 May;67(5):2349-56
10225894
J Immunol. 2007 Aug 1;179(3):1438-48
17641009
J Immunol. 2001 Dec 15;167(12):7102-10
11739532
Infect Immun. 1997 Apr;65(4):1139-46
9119443
Trends Immunol. 2007 Jan;28(1):33-8
17126601
J Immunol. 1997 Jul 1;159(1):401-8
9200479
Immunity. 2003 Nov;19(5):641-4
14614851
J Exp Med. 2001 Feb 5;193(3):339-51
11157054
Nat Rev Immunol. 2003 Feb;3(2):133-46
12563297
Eur J Immunol. 1995 Jan;25(1):200-6
7843232
J Clin Invest. 2002 Jul;110(2):165-75
12122108
Trans Am Clin Climatol Assoc. 2005;116:221-6; discussion 226-7
16555616
J Biol Chem. 1983 Jan 10;258(1):636-42
6336756
J Immunol. 1999 Sep 1;163(5):2902-8
10453037
Immunology. 2007 Nov;122(3):350-61
17623032
J Biol Chem. 2001 Mar 16;276(11):7899-905
11110796
Nat Med. 2005 Nov;11(11):1180-7
16208318
Am J Respir Cell Mol Biol. 2007 May;36(5):515-9
17255554
Infect Immun. 2006 Jan;74(1):469-80
16369003
J Invest Dermatol. 2001 Sep;117(3):618-26
11564168
Proc Natl Acad Sci U S A. 1990 Sep;87(17):6808-12
2204066
Immunity. 2000 Nov;13(5):715-25
11114383
Virology. 2007 Jun 20;363(1):48-58
17331554
J Immunol. 1997 Jan 1;158(1):376-83
8977213
J Immunol. 1997 May 1;158(9):4381-8
9127002
J Exp Med. 1989 Sep 1;170(3):827-45
2504877
Infect Immun. 2004 May;72(5):2956-63
15102808
J Exp Med. 1994 Apr 1;179(4):1367-71
7908325
Cell. 1986 Jan 31;44(2):283-92
3943125
J Exp Med. 2006 Jul 10;203(7):1805-15
16818672
J Biol Chem. 1992 Jul 25;267(21):14703-12
1634515
J Immunol. 2007 May 1;178(9):5828-38
17442967
J Virol. 2001 Apr;75(7):3343-51
11238860
J Neurochem. 2003 Jul;86(2):519-28
12871593
Eur J Immunol. 1999 Jun;29(6):2007-13
10382764
Am J Respir Crit Care Med. 2003 Jan 15;167(2):171-9
12406830
J Exp Med. 1995 Mar 1;181(3):961-71
7869054
Eur J Immunol. 1997 Oct;27(10):2626-33
9368619
J Virol. 2005 Dec;79(23):14933-44
16282492
Am J Respir Crit Care Med. 2006 Aug 15;174(4):461-70
16728708
Am J Pathol. 1998 Jan;152(1):101-11
9422528
Nat Rev Immunol. 2005 Jul;5(7):521-31
15999093
J Immunol. 2003 Dec 15;171(12):6866-74
14662893